DynaMed vs OpenEvidence cost, evidence grading and which one to pay for

DynaMedex costs $599 a year for a practicing clinician, $675 a year with Dyna AI, and $149 for students, read on EBSCO's dynamedex.com store on 13 October 2026. Each subscription runs one year and renews automatically on its anniversary, and EBSCO offers a 30-day free trial and a 60-day money-back guarantee. Plain DynaMed, without the "ex", is not on the individual store; hospitals license it through a quote. Every access route is laid out on our DynaMed and DynaMedex cost page.

OpenEvidence costs nothing. Its homepage says it is free for verified US healthcare professionals, and free and unlimited, and there is no paid tier to upgrade to. The verification gate is the NPI, so anyone without one (most office staff, many international users) is locked out; we cover who gets in on the OpenEvidence cost page.

So over three years the gap is $1,797 to $2,025 for one clinician, before any society or employer pays it for you. That is the number to weigh against what the paid layer actually adds, which is the next section.

OpenEvidence is faster for a narrow question, and DynaMed is more defensible for a consequential one. Ask OpenEvidence whether a drug needs adjusting in a given setting and you get a short written answer with the papers linked. Open the same topic in DynaMed and you get a structured summary in which each recommendation carries an evidence level that an editor assigned after reading the studies. The first saves time. The second saves you the appraisal.

Neither is a judgment-free shortcut. A generated answer can lean on a weak source or summarize a study loosely, which is why reading the citations matters. An edited reference can lag a new trial by weeks. The workable habit most clinicians land on is the obvious one: the free engine for quick questions, the graded reference when you need to defend the decision.

Drug content is the biggest difference, and the one comparisons usually skip. DynaMedex is DynaMed plus Micromedex drug information: adult, pediatric and neonatal dosing, interactions and IV compatibility, under the same login. If you are already paying for a separate drug database, that bundle may replace it, so price the overlap before you renew anything. Our Lexicomp vs Micromedex page shows what the Micromedex content covers.

The second difference is credit. DynaMedex tracks CME, CE and MOC as you use it, configured to your profile. That matters if your state board or specialty board counts hours, because the credit follows reading you do anyway.

The third is how the AI is framed. Dyna AI is a search layer over DynaMed's own edited content, so its answers stay inside material EBSCO's editors have appraised. OpenEvidence draws on a much wider body of literature, including its NEJM, JAMA, Nature Portfolio and Cochrane agreements, which makes it broader and also means more of the appraisal falls to you. For individuals, EBSCO sells the Dyna AI tier in the USA only.

Often, yes. ACP lists DynaMedex with Dyna AI as included with ACP membership, so an internist who already pays ACP dues is covered without a separate subscription. Many US hospitals, health systems and medical schools license DynaMed for everyone on their network, so ask your medical librarian before you put a card in.

If neither applies and you prescribe on your own, compare the free trial against your actual week. Thirty days is enough to see whether you open DynaMed for graded recommendations or just for drug doses. If it is mostly doses, a drug-focused tool is cheaper; the best drug reference app guide prices the options from free to $599.

DynaMed and OpenEvidence both wait for a question. Neither looks at the prescription you are about to sign and tells you, unprompted, that the new drug interacts with something already on the list, that the eGFR you charted calls for a lower dose, or that a documented allergy rules out the obvious choice. To get that from either one, you have to think to ask, separately, each time.

Prescriber.io is built for that step. Enter the drug and the patient context once and one card returns interactions across the full medication list, contraindications, allergy conflicts and renal and hepatic dose adjustments, each with the reference it came from. Plans start at $24 per clinician per month billed annually, and the details are on our pricing page. It is decision support: you review every flag, verify it against official sources and sign.